Early implementation of treatment with biologic or targeted synthetic DMARDs after methotrexate failure did not prevent the ...
Miracles Healthcare combines a team of experienced specialists with the latest medical technology, ensuring that each patient ...
A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active ...
Colchicine fails to improve knee pain, function, or size of synovial effusions with painful knee osteoarthritis (OA), ...
More than half the women in the treat-to-target group conceived within 3 months vs a median of 6.5 months for those in the ...
Knee injuries are common in athletes, accounting for 41% of all athletic injuries. But knee injuries aren't limited to ...
Both studies were presented at the American College of Rheumatology (ACR) annual meeting.
Not only is Wegovy extremely effective (people lose about 15% of their body weight in a year), it also appears to have many ...
The Food and Drug Administration has granted Fast Track designation to GNSC-001 for the treatment of osteoarthritis of the knee.
The use of biologic and targeted therapies for children with juvenile idiopathic arthritis (JIA) surpassed more typical therapies in recent years, according to researchers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback